Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Smith & Nephew LSE:SN. London Ordinary Share GB0009223206 ORD USD0.20
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -4.00p -0.28% 1,442.00p 1,441.00p 1,442.00p 1,444.50p 1,435.00p 1,436.00p 94,820 09:13:50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 3,527.9 650.8 65.0 21.2 12,632.92

Smith & Nephew Share Discussion Threads

Showing 801 to 825 of 825 messages
Chat Pages: 33  32  31  30  29  28  27  26  25  24  23  22  Older
DateSubjectAuthorDiscuss
12/12/2018
11:12
Strange. Nothing spectacular regarding last results. Forecast looks on target and inline with sector. New CEO is 6months in now so is likely going to start making significant change anytime, perhaps Market are expecting good things from Namal.
kknight01
07/12/2018
14:28
Stock up a short 20% in just over 6 weeks in weak market.Bid?
steeplejack
02/11/2018
11:03
Pleased to see the back of Olivier, debatable what he actually achieved. Some very highly priced acquisitions which failed to live up to high expectations?.
essentialinvestor
02/11/2018
08:33
Global medical technology business Smith & Nephew reported a 3% increase in third-quarter underlying revenue and reconfirmed its full-year guidance as it implemented a new global commercial model. The firm said on Thursday that growth in its US and Emerging Markets segments had supported the 3% increase to $1.169bn, "We expect underlying revenue growth to be in the lower half of the 2-3% range and, as a result of a favourable legal settlement and improved cost control, trading profit margin to be above that achieved in 2017," CEO Namal Nawana said. However, revenue declined 1% in its Other Established Markets, where Europe was negatively impacted by challenging conditions in Germany and the UK, while revenue from its Advanced Wound Bioactives franchise fell 7%. Looking forward, the Group did not believe the UK's decision to leave the EU would have a significant impact on its long-term ability to conduct business into and out of the EU or UK. It was making "good progress" with preparations of the various scenarios. In order for the company to leverage its strength as a portfolio medical device company and unlock its growth potential, it was implementing a new global commercial model. Under this, a president would be responsible for each of its three specialised global marketing franchises - Orthopaedics, Sports Medicine/ENT and Wound. Aligned with and supporting the franchises would be presidents and regional commercial organisations for Europe, Middle East, and Africa (EMEA), and Asia Pacific (APAC), while the franchise presidents would also have commercial responsibility for the US.
broadwood
01/11/2018
08:23
Market likes. Improved underlying revenue growth in the third quarter was led by growth in the US and Emerging Markets. We are on-track to deliver our full year guidance. "These results were achieved whilst successfully redesigning how we will run the company. There is still more to do, and I am pleased with the pace of progress and engagement across the organisation." If there's a bidder lurking, nows the time.
broadwood
26/7/2018
06:42
Accounts our for 1/2 year - Very much steady as she goes - https://www.investegate.co.uk/smith---38--nephew-plc--sn--/rns/half-year-report/201807260700188013V/ Nothing to shout about (imo) share price reaction will very much depend on forecasts (anyone got them?)
pugugly
04/5/2018
07:24
Elliott called for the company to be broken up last year, after which Mr Bohuon unveiled a cost-cutting plan which he said would deliver $160m of savings by 2022.Analysts at Bernstein said: "S&N's overall performance on both growth and margins has remained disappointing. From here it is all about execution." Daily Telegraph
steeplejack
03/5/2018
09:49
Yes , got to be only a matter of time.
its the oxman
03/5/2018
08:28
Something has to happen here. These guys are vulnerable now. Would not be surprised if Elliot Management makes a return.
basil brush1
03/5/2018
07:25
These less than brilliant results would make it an opportune time to strike for a possible bidder.
broadwood
03/5/2018
07:17
The guidance has been trimmed from revenue growth of 3-4% at the time of the finals to 2-3% now.The suggestion is that things will stabilise and return to a more normal pattern in the rest of the year.Emerging markets are encouraging.Whether this update is worth over 7% off the share price is questionable especially given the corporate activity just now in the sector.Yet the shares have been very strong of late and are vulnerable to top slicing.Maybe I'm too simplistic but I never really worry about my holding in Smith & Nephew.I always feel that if things take an enduring turn for the worse,someone will take the company over.
steeplejack
03/5/2018
06:43
I think you are too pessimistic. I am seeing a P/E of 20 on 2018 EPS before this update, while Stryker is 26. Emerging markets growing at 9% and SN has very little debt.
basil brush1
03/5/2018
06:25
Flat earnings and a P/E of 22 hardly makes it remotely attractive. Also I see plenty of alternative wound care therapies coming through in coming years. Look at Origin WW as an example. Technology been given fast track approval by FDA.
rock star
23/4/2018
18:35
I bought these on the bid speculation awhile back. This sounds interesting. Smith & Nephew was top of the blue chip pile as Dutch giant Philips' first-quarter results revealed strong growth in medical equipment, which was music to the ears of the London-listed maker of artificial shoulders, knees and possibly toes. A further tonic for S&N shares was bid speculation bubbling up again as City traders pointed to US-based Stryker, based in the marvellously named Kalamazoo, Michigan, being a possible suitor after four years ago confirming it had been been looking at a potential takeover.
broadwood
23/4/2018
14:48
Why today? News?
its the oxman
23/4/2018
14:43
Is this the big breakout?
basil brush1
04/4/2018
15:13
Any views on new CEO? He sold Alere to Abbott in 2017 for $5.3 billion. No one seems to care?
basil brush1
24/1/2018
08:00
Scope to have a run back over 1300p with lower tax guidance.
its the oxman
22/1/2018
10:20
Strykers full results are on Jan 30, the next few weeks will be interesting. Stryker provides 2017 preliminary net sales results By GlobeNewswire, January 09, 2018, 08:15:00 AM EDT Kalamazoo, Michigan - January 9, 2018 - Stryker Corporation (NYSE:SYK) announced today that preliminary results for the fourth quarter and full year 2017 were: Preliminary Fourth Quarter Highlights Net sales grew 10.0% to $3.5 billion (8.7% constant currency) Orthopaedics 8.1 % or 6.8 % constant currency MedSurg 10.9 % or 9.8 % constant currency Neurotechnology and Spine 11.5 % or 10.3 % constant currency Preliminary Full Year Highlights Net sales grew 9.9% to $12.4 billion (9.8% constant currency) Orthopaedics 6.6 % or 6.5 % constant currency MedSurg 13.6 % or 13.4 % constant currency Neurotechnology and Spine 8.2 % or 8.3 % constant currency Preliminary consolidated net sales of $3.5 billion and $12.4 billion increased 10.0% and 9.9% as reported in the fourth quarter and full year. Excluding the impact of foreign currency and acquisitions, net sales increased 8.1% and 7.1% in the fourth quarter and full year. Based on our year-to-date performance, we expect 2017 adjusted net earnings per diluted share(a) to be toward the high end of our previously announced range of $6.45 to $6.50. The foreign currency exchange impact on net sales in the fourth quarter was positive of approximately 1.2% and nominal in the full year. "We continued our momentum with strong organic sales growth of 8% for the fourth quarter and 7% for the full year," said Kevin A. Lobo, Chairman and Chief Executive Officer. "I would like to thank our teams for delivering these results, which were well balanced across businesses and geographies. We are also driving innovation through R&D and acquisitions that will fuel future growth. These investments will enable us to deliver sales growth at the high end of med tech and leveraged earning gains."
basil brush1
22/1/2018
10:16
Good luck! IMO these UK companies that report in foreign currencies lose out both ways, because the US investors dont understand the accounting while the UK investors are confused by the currency. SN has fallen nearly £2 since October, the market seems to be discounting the worst. But meanwhile Stryker keeps marching on.
basil brush1
21/1/2018
12:42
Bloody well hope there is a bid. Sold a load just under 1400p and now bought them back and more besides. Poor performer over 12 months. Hoping for a bounce regardless with results. We will see.
its the oxman
19/1/2018
08:39
imo lots of support at 1230. the big question is will there be a bid before the new CEO is appointed? looks vulnerable as share price has not changed in dollar terms in nearly 4 years. Stryker has doubled in the same period.
basil brush1
18/1/2018
16:25
Could have further to fall (imo) 11-Oct-17Citigroup Sell Now 1,233.50 Then 1,359.00 New target 1,160.00
pugugly
17/1/2018
11:18
these were 1440 less than 3 months back. are the powers than be managing the price down so to get a bid in at not much higher than the October highs?
basil brush1
16/1/2018
20:07
As a quality operator surely SN will get some bid speculation this year. Must be so tempting now it's slipped back to 1250p.
its the oxman
Chat Pages: 33  32  31  30  29  28  27  26  25  24  23  22  Older
Your Recent History
LSE
SN.
Smith & Ne..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190117 09:29:03